Medicine delivery company IntelGenx Corp. IGXTs development candidate buprenorphine buccal filmfor which a Abbreviated New Drug Application (ANDA) was filed by Chemo Research SL through its agent and its generic pharmaceutical affiliate Xiromed LLC (the American division of Insud Pharma SL) received a FDA Generic Drug User Fees Act (GDUFA) date April 28, 2023.

According FDA pagethe 2012 Generic Drug User Fee Changes (GDUFA) are designed to accelerate public access to safe and effective generic drugs and reduce costs to industrywith the ultimate objective to ensure patients access to “safe, high quality and affordable generic medicines”.

This law obliges the industry to pay user fees to cover the costs of reviewing generic drug applications and inspecting facilities in a in right time. As the ANDA filed by IntelGenx received a final review date for 2023, if the result is positivethe company would shortly thereafter be permitted to commence market his generic drug.

Dr. Horst G. Zerbe, CEO of IntelGenx says the company is happy that its long-term partnership with Xiromed resulted in the regulatory filing with the FDA indicating that it will complete its review early in the second quarter of next year.

“Our generic version of Belbuca is designed to be a bioequivalent alternative at lower cost for patients. We look forward to the FDA’s decision and, assuming a positive outcome, commercialization of buprenorphine buccal film as soon as possible,” explained the CEO.

Belbuca, first approved by the FDA in 2015is applied to the oral or buccal mucosa every 12 hours and comes in seven strengths ranging from 0.075mg to 0.9mg.

Like its predecessor, Generic Buprenorphine Buccal Film is designed as a opioid to manage severe pain requiring long-term daily treatment where other pain treatments are inadequate. Its development, which began in September 2016, incorporates IntelGenx technology versafilm technology in a new formulation developed by IntelGenx and Chemo.

More generally, IntelGenx cinematic technologies partner with and support new generation drugs treat unmet medical conditions, such as polymer buccal film containing a synthetic drug of the DMT type recently developed for a psychedelic company atai ATAI.

picture by Hans Reniers on Unsplash


Nine Canadian entrepreneurs selected for the EY Entrepreneurial Winning Women™ North America Class of 2022


Canadian company announces acquisition agreement with WillowTree -

Check Also